55. Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine. NDT 2015, 30 (suppl 4):iv105-iv112.

Lambers Heerspink HJ, Oberbauer R, Perco P, Heinzel A, Heinze G, Mayer G, Mayer B

54. Molecular disease presentation in diabetic nephropathy. NDT 2015, 30 (suppl 4):iv17-iv25.

Heinzel A, Mühlberger I, Stelzer G, Lancet D, Oberbauer R, Martin M, Perco P.

53. Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes. NDT 2015, 30 (suppl 4):iv86-iv95

Pena MJ, de Zeeuw D, Mischak H, Jankowski J, Oberbauer R, Woloszczuk W, Benner J, Dallmann G, Mayer B, Mayer G, Rossing P, Lambers Heerspink HJ

52. Prediction of prevalence of chronic kidney disease in diabetic patients in countries of the European Union up to 2025. NDT 2015, 30 (suppl 4):iv113-iv118. (IF 4.8)

Kainz A, Hronsky M, Stel VS, Jager KJ, Geroldinger A, Dunkler D, Heinze G, Tripepi G, Oberbauer R

51. Population Attributable Fraction of Modifiable Lifestyle Factors for Chronic Kidney Disease and Mortality in Individuals with Diabetes. NDT Supp 2015 (in press)

Dunkler D, Kohl M, Mann, Teo, Yusuf, Oberbauer R

50. Genome-wide Studies to Identify Risk Factors for Kidney Disease with a Focus on Patients with Diabetes. NDT 2015, 30 (suppl 4):iv26-iv34 (IF 4.8)

Regele F, Jelencsics K, Shiffman D, Pare G, McQueen MJ, Mann JEF, Oberbauer R

49. microRNAs in Kidney Transplantation. Nephrol Dial Transplant 2015; 30(6):910-917.

Wilflingseder J, Reindl-Schwaighofer R, Sunzenauer J, Kainz A, Heinzel A, Mayer B, Oberbauer R

SCIENTIFIC COLLABORATIONS